News | August 03, 2021
Evexia Lifecare to manufacture API of Isometa
Robust demand for the product across the Middle East, Africa and Latin America
Robust demand for the product across the Middle East, Africa and Latin America
Drug formulations and biologics make impressive gains
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
India business is growing as per projections; whereas US business will bounce back soon.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Turnover of API division of ISLL stood at Rs 856.58 crore
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
Price band in the range of Rs 933 to Rs 954
Subscribe To Our Newsletter & Stay Updated
